Form 8-K - Current report:
SEC Accession No. 0001628280-24-034766
Filing Date
2024-08-05
Accepted
2024-08-05 16:34:24
Documents
14
Period of Report
2024-08-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20240803.htm   iXBRL 8-K 26788
2 EX-10.1 exhibit101transitionagreem.htm EX-10.1 47536
  Complete submission text file 0001628280-24-034766.txt   214218

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20240803.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20240803_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20240803_pre.xml EX-101.PRE 13060
16 EXTRACTED XBRL INSTANCE DOCUMENT espr-20240803_htm.xml XML 2835
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 241175319
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)